PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsIdecabtagene vicleucel
Abecma(idecabtagene vicleucel)
Abecma (idecabtagene vicleucel) is a gene pharmaceutical. Idecabtagene vicleucel was first approved as Abecma on 2021-03-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat blood protein disorders, cardiovascular diseases, hematologic diseases, hemic and lymphatic diseases, and hemorrhagic disorders amongst others.
Download report
Favorite
BMS
Case Study: Multiple Myeloma
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Abecma
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Idecabtagene vicleucel
Tradename
Proper name
Company
Number
Date
Products
Abecmaidecabtagene vicleucelCelgeneN-125736 RX2021-03-03
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
abecmaBiologic Licensing Application2025-03-26
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
multiple myeloma—D009101C90.0
Agency Specific
FDA
EMA
Expiration
Code
idecabtagene vicleucel, Abecma, Celgene Corporation, a Bristol-Myers Squibb Company
2028-03-26Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
Q2055
Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Clinical
Clinical Trials
114 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101—C90.05334711090
Plasma cell neoplasmsD054219——503071782
NeoplasmsD009369—C80———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C9524——16
Autoimmune diseasesD001327EFO_0000540M30-M3651——16
Plasma cell leukemiaD007952—C90.113——15
LymphomaD008223—C85.921——13
AmyloidosisD000686EFO_1001875E8511——13
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0—1——12
B-cell lymphomaD016393———1——12
Healthy volunteers/patients———21———2
Lupus nephritisD008181EFO_0005761—21———2
NephritisD009393—N0521———2
Show 2 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Systemic lupus erythematosusD008180EFO_0002690M324————4
Myasthenia gravisD009157EFO_0004991G70.04————4
VasculitisD014657EFO_0006803M313————3
Anti-neutrophil cytoplasmic antibody-associated vasculitisD056648—I77.823————3
Hemolytic anemia autoimmuneD000744EFO_1001264D59.103————3
Hemolytic anemiaD000743—D55-D593————3
SyndromeD013577——2————2
Non-hodgkin lymphomaD008228—C85.91———12
Immunoglobulin g4-related diseaseD000077733—D89.842————2
Multiple sclerosisD009103EFO_0003885G352————2
Show 19 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vaccine-preventable diseasesD000079263——————11
B-cell chronic lymphocytic leukemiaD015451—C91.1————11
Immunoglobulin light-chain amyloidosisD000075363——————11
Lymphoid leukemiaD007945—C91————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIdecabtagene vicleucel
INNidecabtagene vicleucel
Description
Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma.
Classification
Gene
Drug classAntineoplastic
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4298199
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID8PX1X7UG4D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Abecma – Bristol Myers Squibb
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,307 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abecma
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,000 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use